Using our anti-CELF2 Triple A polyclonal antibody, this study explores the expression profile and mode of action of CELF2 (an RNA-binding protein) in a collection of human glioblastoma samples and patient-derived glioma stem cells.
The results reveal high levels of CELF2 expression in proliferating the OLIG2-positive glioblastoma cells and a lack of expression in other tumor cells, illustrating the complexity of intra-tumor heterogeneity in glioblastoma, and overall supporting the oncogenic role for CELF2 in promoting the stemness and proliferation of glioblastoma cells.